HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Stocks · News reference
Wedbush Adjusts Beam Therapeutics Price Target to $28
Wedbush Securities adjusted its price target for Beam Therapeutics from $65 to $28 while maintaining an 'Outperform' rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.